A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer

Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study

(2013) Ali Inal et al.   Asian Pacific Journal of Cancer Prevention

Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010

(2013) Kyu-Won Jung et al.   Cancer Research and Treatment

A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer

(2012) Gun Min Kim et al.   EUROPEAN JOURNAL OF CANCER

Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel

(2011) Carolien P. Schröder et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Docetaxel: its role in current and future treatments for advanced gastric cancer

(2009) Masahiko Nishiyama et al.   Gastric Cancer

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group

(2008) J G Kim et al.   BRITISH JOURNAL OF CANCER

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2008) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE